Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
PRQR Stock Forecast 2025-2026
$2.22
Current Price
$233.86M
Market Cap
Buy 6
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to PRQR Price Targets
+530.6%
To High Target of $14.00
+260.4%
To Median Target of $8.00
+80.2%
To Low Target of $4.00
PRQR Price Momentum
-19.3%
1 Week Change
-11.2%
1 Month Change
-41.1%
1 Year Change
-16.2%
Year-to-Date Change
-47.3%
From 52W High of $4.21
+107.5%
From 52W Low of $1.07
📊 TOP ANALYST CALLS
Did PRQR Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if ProQR is one of their latest high-conviction picks.
Latest PRQR Stock Price Targets & Analyst Predictions
Based on our analysis of 12 Wall Street analysts, PRQR has a bullish consensus with a median price target of $8.00 (ranging from $4.00 to $14.00). The overall analyst rating is Strong Buy (9.7/10). Currently trading at $2.22, the median forecast implies a 260.4% upside. This outlook is supported by 6 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Steven Seedhouse at Raymond James, projecting a 530.6% upside. Conversely, the most conservative target is provided by Keay Nakae at Chardan Capital, suggesting a 80.2% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PRQR Analyst Ratings
6
Buy
0
Hold
0
Sell
PRQR Price Target Range
Low
$4.00
Average
$8.00
High
$14.00
Current: $2.22
Latest PRQR Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PRQR.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 4, 2025 | Chardan Capital | Keay Nakae | Buy | Maintains | $4.00 |
| Aug 8, 2025 | Chardan Capital | Keay Nakae | Buy | Maintains | $4.00 |
| Jun 27, 2025 | JMP Securities | Jonathan Wolleben | Market Outperform | Reiterates | $8.00 |
| Jun 27, 2025 | Cantor Fitzgerald | Timur Ivannikov | Overweight | Reiterates | $8.00 |
| May 13, 2025 | Oppenheimer | Andreas Argyrides | Outperform | Maintains | $9.00 |
| Apr 29, 2025 | Evercore ISI Group | Gavin Clark-Gartner | Outperform | Initiates | $5.00 |
| Mar 14, 2025 | HC Wainwright & Co. | Andrew Fein | Buy | Maintains | $12.00 |
| Mar 14, 2025 | Chardan Capital | Keay Nakae | Buy | Maintains | $4.00 |
| Feb 12, 2025 | Jones Trading | Catherine Novack | Buy | Initiates | $11.00 |
| Dec 12, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $10.00 |
| Dec 12, 2024 | JMP Securities | Jonathan Wolleben | Market Outperform | Reiterates | $8.00 |
| Dec 12, 2024 | Chardan Capital | Keay Nakae | Buy | Maintains | $4.00 |
| Nov 8, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Maintains | $10.00 |
| Oct 29, 2024 | Raymond James | Steven Seedhouse | Strong Buy | Upgrade | $14.00 |
| May 10, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $5.00 |
| May 10, 2024 | Chardan Capital | Keay Nakae | Buy | Maintains | $2.50 |
| Apr 18, 2024 | Citigroup | Yigal Nochomovitz | Neutral | Maintains | $2.00 |
| Mar 14, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $5.00 |
| Mar 14, 2024 | Chardan Capital | Keay Nakae | Buy | Maintains | $2.50 |
| Mar 14, 2024 | HC Wainwright& Co. | Buy | Reiterates | $N/A |
ProQR Therapeutics N.V. (PRQR) Competitors
The following stocks are similar to ProQR based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
ProQR Therapeutics N.V. (PRQR) Financial Data
ProQR Therapeutics N.V. has a market capitalization of $233.86M with a P/E ratio of -6.9x. The company generates $18.55M in trailing twelve-month revenue with a -264.8% profit margin.
Revenue growth is -26.8% quarter-over-quarter, while maintaining an operating margin of -387.1% and return on equity of -103.8%.
Valuation Metrics
Market Cap
$233.86M
Enterprise Value
$165.61M
P/E Ratio
-6.9x
PEG Ratio
0.0x
Price/Sales
14.5x
Growth & Margins
Revenue Growth (YoY)
-26.8%
Gross Margin
N/A
Operating Margin
-387.1%
Net Margin
-264.8%
EPS Growth
-30.1%
Financial Health
Cash/Price Ratio
+45.7%
Current Ratio
3.4x
Debt/Equity
28.9x
ROE
-103.8%
ROA
-24.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
ProQR Therapeutics N.V. (PRQR) Business Model
About ProQR Therapeutics N.V.
What They Do
Develops RNA-based therapies for genetic disorders.
Business Model
ProQR Therapeutics generates revenue through the development and commercialization of innovative RNA-based therapies targeting genetic disorders. By focusing on unmet medical needs, particularly in genetic eye diseases, the company aims to create effective treatment options that can lead to partnerships with larger pharmaceutical companies and potential licensing agreements.
Additional Information
Founded in 2012 and based in the Netherlands, ProQR Therapeutics is recognized for its pioneering work in RNA-editing technologies. The company is committed to advancing genetic research and has a robust pipeline of therapies, which positions it as a significant player in the biotechnology sector, particularly in the life sciences and healthcare fields.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
166
CEO
Mr. Daniel Anton de Boer
Country
Netherlands
IPO Year
2014
Website
www.proqr.comProQR Therapeutics N.V. (PRQR) Latest News & Analysis
Latest News
Quick Summary
ProQR Therapeutics (Nasdaq: PRQR) reported its Q3 2025 financial results and business update, focusing on its RNA therapies and Axiomer™ RNA editing technology.
Why It Matters
ProQR's Q3 financial results and updates on its RNA editing platform could impact stock performance, reflecting the company's growth potential and innovation in biopharmaceuticals.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
ProQR (PRQR) reported a quarterly loss of $0.12 per share, worse than the expected loss of $0.10, and a decline from a loss of $0.11 per share year-over-year.
Why It Matters
ProQR's larger-than-expected quarterly loss signals potential operational challenges, possibly impacting investor confidence and stock performance.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
ProQR Therapeutics will host a shareholder/analyst call on November 3, 2025, at 10:00 AM EST, featuring key executives and various analysts from notable firms.
Why It Matters
The upcoming shareholder call may provide insights into ProQR's strategic direction, financial health, and upcoming product developments, influencing stock performance and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
ProQR Therapeutics has received EMA authorization for a Phase 1 clinical trial of AX-0810, targeting cholestatic diseases. The trial will involve healthy volunteers.
Why It Matters
ProQR's Phase 1 study authorization for AX-0810 signifies potential advancements in RNA therapies, impacting future valuations and market confidence in innovative treatments for cholestatic diseases.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
ProQR Therapeutics (Nasdaq: PRQR) will participate in upcoming investor conferences, focusing on its RNA therapies and ADAR-mediated Axiomer™ RNA editing technology.
Why It Matters
ProQR's participation in investor conferences signals engagement and potential growth in RNA therapies, which may boost investor confidence and interest in the company's future prospects.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
ProQR Therapeutics reported its Q2 2025 financial results and business update, focusing on its Axiomer RNA editing technology platform. The report covers results for the period ending June 30, 2025.
Why It Matters
ProQR's quarterly results and updates on its RNA therapies could impact stock performance, signaling investor confidence or concerns about future growth and innovation in biotech.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About PRQR Stock
What is ProQR Therapeutics N.V.'s (PRQR) stock forecast for 2026?
Based on our analysis of 12 Wall Street analysts, ProQR Therapeutics N.V. (PRQR) has a median price target of $8.00. The highest price target is $14.00 and the lowest is $4.00.
Is PRQR stock a good investment in 2026?
According to current analyst ratings, PRQR has 6 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.22. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PRQR stock?
Wall Street analysts predict PRQR stock could reach $8.00 in the next 12 months. This represents a 260.4% increase from the current price of $2.22. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is ProQR Therapeutics N.V.'s business model?
ProQR Therapeutics generates revenue through the development and commercialization of innovative RNA-based therapies targeting genetic disorders. By focusing on unmet medical needs, particularly in genetic eye diseases, the company aims to create effective treatment options that can lead to partnerships with larger pharmaceutical companies and potential licensing agreements.
What is the highest forecasted price for PRQR ProQR Therapeutics N.V.?
The highest price target for PRQR is $14.00 from Steven Seedhouse at Raymond James, which represents a 530.6% increase from the current price of $2.22.
What is the lowest forecasted price for PRQR ProQR Therapeutics N.V.?
The lowest price target for PRQR is $4.00 from Keay Nakae at Chardan Capital, which represents a 80.2% increase from the current price of $2.22.
What is the overall PRQR consensus from analysts for ProQR Therapeutics N.V.?
The overall analyst consensus for PRQR is bullish. Out of 12 Wall Street analysts, 6 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $8.00.
How accurate are PRQR stock price projections?
Stock price projections, including those for ProQR Therapeutics N.V., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: November 9, 2025 6:52 AM UTC